Citizens Jmp Issues Pessimistic Forecast for Structure Therapeutics (NASDAQ:GPCR) Stock Price

Structure Therapeutics (NASDAQ:GPCR) had its target price dropped by equities researchers at Citizens Jmp from $120.00 to $113.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price target would indicate a potential upside of 79.42% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Morgan Stanley boosted their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. JPMorgan Chase & Co. lifted their price target on Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, January 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Thursday, January 22nd. Guggenheim boosted their target price on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Finally, HC Wainwright upped their price target on Structure Therapeutics from $60.00 to $90.00 and gave the company a “buy” rating in a report on Friday, December 19th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $105.50.

Structure Therapeutics Stock Performance

GPCR stock opened at $62.98 on Friday. The company’s 50 day moving average price is $75.41 and its 200 day moving average price is $46.73. The firm has a market capitalization of $4.45 billion, a price-to-earnings ratio of -79.72 and a beta of -2.06. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Equities analysts forecast that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley boosted its holdings in shares of Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares in the last quarter. Wellington Management Group LLP raised its holdings in Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after purchasing an additional 1,432,797 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Structure Therapeutics by 477.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after purchasing an additional 1,381,745 shares during the period. Avoro Capital Advisors LLC lifted its position in Structure Therapeutics by 21.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after purchasing an additional 1,150,000 shares during the period. Finally, Capitolis Liquid Global Markets LLC purchased a new stake in Structure Therapeutics in the 4th quarter valued at approximately $61,086,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.